Page 1069 - Hall et al (2015) Principles of Critical Care-McGraw-Hill

16 References

for Disease Control and Prevention. MMWR Recomm Rep. catheters in hospitalized patients with cancer. Ann Intern Med.
2002;51(RR-10):1-29. 1999;131(9):641-647.
466. Raad I, Hanna H, Maki D. Intravascular catheter-related infec- 483. Martinez JA, DesJardin JA, Aronoff M, Supran S, Nasraway SA,
tions: advances in diagnosis, prevention, and management. Snydman DR. Clinical utility of blood cultures drawn from cen-
Lancet Infect Dis. 2007;7(10):645-657. tral venous or arterial catheters in critically ill surgical patients.
467. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC Crit Care Med. January 2002;30(1):7-13.
definitions for nosocomial infections, 1988. Am J Infect Control. 484. Bouza E, Alvarado N, Alcala L, Perez MJ, Rincon C, Munoz P. A
June 1988;16(3):128-140. randomized and prospective study of 3 procedures for the diag-
468. Emori TG, Culver DH, Horan TC, et al. National nosocomial nosis of catheter-related bloodstream infection without catheter
infections surveillance system (NNIS): description of surveil- withdrawal. Clin Infect Dis. 2007;44(6):820-826.
lance methods. Am J Infect Control. February 1991;19(1):19-35. 485. Chee L, Brown M, Sasadeusz J, MacGregor L, Grigg AP.
469. Maki DG, Kluger DM, Crnich CJ. The risk of bloodstream Gram-negative organisms predominate in Hickman line-related
infection in adults with different intravascular devices: a sys- infections in non-neutropenic patients with hematological
tematic review of 200 published prospective studies. Mayo Clin malignancies. J Infect. April 2008;56(4):227-233.
Proc. September 2006;81(9):1159-1171. 486. Sakoulas G, Moise-Broder PA, Schentag J, Forrest A,
470. Safdar N, Mermel LA, Maki DG. The epidemiology of catheter- Moellering RC Jr, Eliopoulos GM. Relationship of MIC and
related infection in the critically ill. In: O'Grady N, Pittet D, eds. bactericidal activity to efficacy of vancomycin for treatment of
Catheter-Related Infections in the Critically Ill. New York, NY: methicillin-resistant Staphylococcus aureus bacteremia. J Clin
Kluwer; 2004:1-23. Microbiol. June 2004;42(6):2398-2402.
471. Armstrong CW, Mayhall CG, Miller KB, et al. Clinical predic- 487. Moise PA, Sakoulas G, Forrest A, Schentag JJ. Vancomycin in
tors of infection of central venous catheters used for total paren- vitro bactericidal activity and its relationship to efficacy in clear-
teral nutrition. Infect Control Hosp Epidemiol. 1990;11(2):71-78. ance of methicillin-resistant Staphylococcus aureus bacteremia.
472. Conly JM, Grieves K, Peters B. A prospective, randomized study Antimicrobial Agents Chemother. July 2007;51(7):2582-2586.
comparing transparent and dry gauze dressings for central 488. Lorente L, Jimenez A, Santana M, et al. Microorganisms
venous catheters. J Infect Dis. 1989;159(2):310-319. responsible for intravascular catheter-related bloodstream
473. Lowder JN, Lazarus HM, Herzig RH. Bacteremias and funge- infection according to the catheter site. Crit Care Med. October
mias in oncologic patients with central venous catheters. Arch 2007;35(10):2424-2427.
Intern Med. 1982;142:1456-1459. 489. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP,
474. Landoy Z, Rotstein C, Lucey J, Fitzpatrick J. Hickman-Broviac Edmond MB. Nosocomial bloodstream infections in US hos-
catheter use in cancer patients. J Surg Oncol. 1984;26(4):215-218. pitals: analysis of 24,179 cases from a prospective nationwide
475. Safdar N, Maki DG. Risk of catheter-related bloodstream infec- surveillance study. Clin Infect Dis. 2004;39(3):309-317.
tion with peripherally inserted central venous catheters used in 490. O’Gara JP, Humphreys H. Staphylococcus epidermidis bio-
hospitalized patients. Chest. August 2005;128(2):489-495. films: importance and implications. J Med Microbiol. July
2001;50(7):582-587.
476. Allen AW, Megargell JL, Brown DB, et al. Venous thrombo-
sis associated with the placement of peripherally inserted 491. McCann MT, Gilmore BF, Gorman SP. Staphylococcus epi-
central catheters. J Vasc Interv Radiol. November-December dermidis device-related infections: pathogenesis and clinical
2000;11(10):1309-1314. management. J Pharm Pharmacol. December 2008;60(12):
1551-1571.
477. Grove JR, Pevec WC. Venous thrombosis related to peripher-
ally inserted central catheters. J Vasc Interv Radiol. July-August 492. Raad I, Kassar R, Ghannam D, Chaftari AM, Hachem R,
2000;11(7):837-840. Jiang Y. Management of the catheter in documented
478. Duerksen DR, Papineau N, Siemens J, Yaffe C. Peripherally catheter-related coagulase-negative staphylococcal bacteremia:
inserted central catheters for parenteral nutrition: a comparison remove or retain? Clin Infect Dis. October 15 2009;49(8):
with centrally inserted catheters. JPEN J Parenter Enteral Nutr. 1187-1194.
1999;23(2):85-89. 493. Luzzati R, Amalfitano G, Lazzarini L, et al. Nosocomial
479. Andes DR, Urban AW, Acher CW, Maki DG. Septic thrombosis candidemia in non-neutropenic patients at an Italian ter-
of the basilic, axillary, and subclavian veins caused by a periph- tiary care hospital. Eur J Clin Microbiol Infect Dis. August
erally inserted central venous catheter. Am J Med. November 2000;19(8):602-607.
1998;105(5):446-450. 494. Nucci M, Anaissie E, Betts RF, et al. Early removal of central
480. Dal Molin A, Rasero L, Guerretta L, Perfetti E, Clerico M. The venous catheter in patients with candidemia does not improve
late complications of totally implantable central venous access outcome: analysis of 842 patients from 2 randomized clinical
ports: the results from an Italian multicenter prospective obser- trials. Clin Infect Dis. August 1, 2010;51(3):295-303.
vation study. Eur J Oncol Nurs. December 2011;15(5):377-381. 495. Laupland KB, Shahpori R, Kirkpatrick AW, Ross T, Gregson
481. Biffi R, de Braud F, Orsi F, et al. Totally implantable central DB, Stelfox HT. Occurrence and outcome of fever in critically
venous access ports for long-term chemotherapy: a prospec- ill adults. Crit Care Med. May 2008;36(5):1531-1535.
tive study analyzing complications and costs of 333 devices 496. Egi M, Morita K. Fever in non-neurological critically ill
with a minimum follow-up of 180 days. Ann Oncol. July patients: a systematic review of observational studies. J Crit
1998;9(7):767-773. Care. October 2012;27(5):428-433.
482. DesJardin JA, Falagas ME, Ruthazer R, et al. Clinical util- 497. Cunha BA. The clinical significance of fever patterns. Infect Dis
ity of blood cultures drawn from indwelling central venous Clin North Am. March 1996;10(1):33-44.

Section05-O-ref.indd 16 1/20/2015 4:51:21 PM